This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Other upper respiratory disease
  • /
  • A multicenter, prospective, noninterventional stud...

A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu.

Read time: 1 mins
Published:1st Oct 2017
Author: <span style="font-size:11.0pt;line-height:107%; font-family:&quot;Nexa Light&quot;;mso-fareast-font-family:Calibri;mso-fareast-theme-font: minor-latin;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language: EN-US;mso-bidi-language:AR-SA">Dollner R, Larsen PL, Dheyauldeen S, Steinsv&aring;g S</span>
Availability: Free full text
Ref.:Allergy Rhinol (Providence). 2017 Oct 1;8(3):148-156.


Allergic Rhinitis and its Impact on Asthma guidelines recently recommended a treatment strategy for allergic rhinitis (AR) based on disease control rather than symptom severity by using a visual analog scale (VAS) to categorize control.


To evaluate the effectiveness of MP-AzeFlu (Dymista®) by using this VAS in routine clinical practice in Norway. MP-AzeFlu comprises a novel formulation that contains azelastine hydrochloride, fluticasone propionate and excipients delivered in a single spray.


This multicenter, prospective, noninterventional study enrolled patients (n = 160) with moderate-to-severe AR and acute symptoms who were eligible to receive treatment with MP-AzeFlu according to its summary of product characteristics. Patients assessed symptom severity by using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP-AzeFlu use on days 0, 1, 3, 7, and after ∼14 days. On day 3, the patients assessed their level of disease control as well controlled, partly controlled, or uncontrolled. The proportion of Norwegian patients who achieved defined VAS score cutoffs for "well-controlled" and "partly controlled" AR were also calculated.


MP-AzeFlu reduced the mean ± standard deviation VAS score from 68.1 ± 16.4 mm at baseline to 37.4 ± 25.9 mm on the last day, a reduction of 30.8 ± 27.2 mm. The results were consistent, irrespective of disease severity, phenotype (i.e., seasonal AR [SAR], perennial AR [PAR], SAR plus PAR, unknown) or age (i.e., 12-17, 18-65, and >65 years). Of the patients (with recorded data), 88.1% considered their symptoms to be partly or well controlled at day 3; and 19.5, 32.0, 50.0, and 61.0% of the patients achieved a ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7, and the last day, respectively.


MP-AzeFlu provided rapid sustained symptom control in a routine clinical practice in Norway, which provided support for its effectiveness for the treatment of AR in real life.

Read abstract on library site

Access full article